Who Generates More Revenue? Takeda Pharmaceutical Company Limited or Amphastar Pharmaceuticals, Inc.

Takeda vs. Amphastar: A Revenue Showdown in Pharmaceuticals

__timestampAmphastar Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20142104610001777824000000
Thursday, January 1, 20152515190001807378000000
Friday, January 1, 20162551650001732051000000
Sunday, January 1, 20172401750001770531000000
Monday, January 1, 20182946660002097224000000
Tuesday, January 1, 20193223570003291188000000
Wednesday, January 1, 20203498460003197812000000
Friday, January 1, 20214377680003569006000000
Saturday, January 1, 20224989870004027478000000
Sunday, January 1, 20236443950004263762000000
Monday, January 1, 20244263762000000
Loading chart...

Data in motion

Revenue Giants: A Tale of Two Pharmaceutical Titans

In the ever-evolving pharmaceutical industry, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Takeda Pharmaceutical Company Limited has consistently outperformed Amphastar Pharmaceuticals, Inc. in terms of revenue. From 2014 to 2023, Takeda's revenue surged by approximately 140%, reaching a staggering 4.26 trillion in 2023. In contrast, Amphastar's revenue grew by about 206%, peaking at 644 million in the same year. Despite Amphastar's impressive growth rate, Takeda's revenue remains over 6,600 times larger, underscoring its dominance in the sector. The data for 2024 is incomplete, but the trend suggests Takeda's continued leadership. This comparison highlights the vast scale differences between global pharmaceutical giants and smaller, yet rapidly growing, companies. As the industry continues to innovate, these revenue trends offer a glimpse into the competitive landscape of pharmaceuticals.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025